| Jessica Lee Benoit, FNP-BC | |
|
5010 Ny-30, Amsterdam, NY 12010 | |
| (518) 842-0017 | |
| Not Available |
| Full Name | Jessica Lee Benoit |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 5010 Ny-30, Amsterdam, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124674957 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 344674 (New York) | Primary |
| Entity Name | Emily T. Etzkorn, M.d., P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396856530 PECOS PAC ID: 1557554235 Enrollment ID: O20101026001217 |
News Archive
Convalescent plasma therapy for COVID-19 patients - an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection - is the focus of a new two-part research initiative at Penn Medicine.
A study of follow-up care for patients with unsatisfactory outcomes from deep brain stimulation (DBS) surgery for movement disorders offers insights into reasons for problems and proposes strategies for improved outcomes. The study will appear in the August print issue of Archives of Neurology.
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent (alirocumab), recommending its approval for use in certain adult patients with hypercholesterolemia.
On the basis of observations of how we interpret the sensation of a simple finger-tap, researchers have advanced our understanding of how the brain sorts important, externally-derived sensations, such as those created by an insect crawling on the skin, from unimportant, internally-derived sensations, such as the brush of one's own hand.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessica Lee Benoit, FNP-BC 113 Fritz Ln, Amsterdam, NY 12010-6567 Ph: (518) 844-5848 | Jessica Lee Benoit, FNP-BC 5010 Ny-30, Amsterdam, NY 12010 Ph: (518) 842-0017 |
News Archive
Convalescent plasma therapy for COVID-19 patients - an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection - is the focus of a new two-part research initiative at Penn Medicine.
A study of follow-up care for patients with unsatisfactory outcomes from deep brain stimulation (DBS) surgery for movement disorders offers insights into reasons for problems and proposes strategies for improved outcomes. The study will appear in the August print issue of Archives of Neurology.
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent (alirocumab), recommending its approval for use in certain adult patients with hypercholesterolemia.
On the basis of observations of how we interpret the sensation of a simple finger-tap, researchers have advanced our understanding of how the brain sorts important, externally-derived sensations, such as those created by an insect crawling on the skin, from unimportant, internally-derived sensations, such as the brush of one's own hand.
› Verified 1 days ago
Dr. William H Forlano, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 119 Holland Circle Dr, Amsterdam, NY 12010 Phone: 518-843-4522 Fax: 518-843-4522 | |
Dr. Robert M Droege, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 119 Holland Circle Dr, Amsterdam, NY 12010 Phone: 518-843-4522 Fax: 518-843-8306 | |
Dr. Michael Angelo Rochet, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 380 Guy Park Ave, Amsterdam, NY 12010 Phone: 518-841-7415 Fax: 518-841-7417 | |
Dr. Mahmood A Khan, M.D., M.B.B.S, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5032 State Highway 30, Medical Plaza, Amsterdam, NY 12010 Phone: 518-842-0200 Fax: 518-842-3003 | |
Sabrina Michelle Bowie, FNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5010 State Highway 30, Ste 204, Amsterdam, NY 12010 Phone: 518-842-8185 Fax: 518-842-8189 | |
Dr. Peter F Diamond, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 119 Holland Circle Dr, Amsterdam, NY 12010 Phone: 518-843-4522 Fax: 518-843-8306 |